Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you consider a stock's sales trends when comparing names? For ideas on how to start your own sales analysis, we ran a screen.

We began by screening the healthcare sector for stocks with high growth prospects, with 5-year projected EPS growth above 15%.

We then screened these names for those with strong trends in revenue compared with inventory over the last year. We screened for companies seeing faster growth in revenue than inventory over the last year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered a good sign.

To screen for healthy liquidity, we also only focused on those companies with inventory declining as a percent of current assets.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research. (click to enlarge)

Tool provided by Kapitall (www.kapitall.com).

Do you think these companies have strong sales trends? Use this list as a starting point for your own analysis. List Average 1-Year Return: 21%.

1. Abaxis Inc. (NASDAQ:ABAX): Develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets. Market cap at $780.27M, most recent closing price at $35.58. EPS growth next 5 years at 18.33%. Revenue grew by 16.69% during the most recent quarter ($42.01M vs. $36M y/y). Inventory grew by 12.52% during the same time period ($20.94M vs. $18.61M y/y). Inventory, as a percentage of current assets, decreased from 16.31% to 15.39% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

2. Accuray Incorporated (NASDAQ:ARAY): Designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used for the treatment of solid tumors. Market cap at $425.58M, most recent closing price at $5.91. EPS growth next 5 years at 30.6%. Revenue grew by 33.65% during the most recent quarter ($100.53M vs. $75.22M y/y). Inventory grew by -16.51% during the same time period ($81.69M vs. $97.84M y/y). Inventory, as a percentage of current assets, decreased from 34.24% to 25.83% during the most recent quarter (comparing 13 weeks ending 2012-06-30 to 13 weeks ending 2011-06-30).

3. Natus Medical Inc. (NASDAQ:BABY): Develops, manufactures, and markets neurodiagnostic and newborn care products worldwide. Market cap at $372.23M, most recent closing price at $12.47. EPS growth next 5 years at 18.5%. Revenue grew by 5.03% during the most recent quarter ($61.01M vs. $58.09M y/y). Inventory grew by -34.82% during the same time period ($25.68M vs. $39.4M y/y). Inventory, as a percentage of current assets, decreased from 28.23% to 15.25% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap at $4.7B, most recent closing price at $38.07. EPS growth next 5 years at 36%. Revenue grew by 12.1% during the most recent quarter ($124.02M vs. $110.63M y/y). Inventory grew by 6.96% during the same time period ($120.12M vs. $112.3M y/y). Inventory, as a percentage of current assets, decreased from 21.84% to 17.63% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

5. Masimo Corporation (NASDAQ:MASI): Develops, manufactures, and markets noninvasive patient monitoring products worldwide. Market cap at $1.38B, most recent closing price at $24.07. EPS growth next 5 years at 16.86%. Revenue grew by 12.07% during the most recent quarter ($122.78M vs. $109.56M y/y). Inventory grew by 1.74% during the same time period ($45.73M vs. $44.95M y/y). Inventory, as a percentage of current assets, decreased from 17.68% to 17.28% during the most recent quarter (comparing 13 weeks ending 2012-06-30 to 13 weeks ending 2011-07-02).

6. Orthofix International N.V. (NASDAQ:OFIX): Designs, develops, manufactures, markets, and distributes medical equipment used principally by musculoskeletal medical specialists for orthopedic applications. Market cap at $818.93M, most recent closing price at $43.17. EPS growth next 5 years at 15.33%. Revenue grew by 2.42% during the most recent quarter ($119.49M vs. $116.67M y/y). Inventory grew by -19.96% during the same time period ($78.42M vs. $97.98M y/y). Inventory, as a percentage of current assets, decreased from 28.31% to 19.78% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

7. ResMed Inc. (NYSE:RMD): Engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Market cap at $5.63B, most recent closing price at $39.62. EPS growth next 5 years at 17.7%. Revenue grew by 8.79% during the most recent quarter ($371.93M vs. $341.89M y/y). Inventory grew by -13.16% during the same time period ($174.35M vs. $200.78M y/y). Inventory, as a percentage of current assets, decreased from 15.53% to 12.81% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

8. Tornier N.V. (NASDAQ:TRNX): Operates as a medical device company that designs, manufactures, and markets devices for joint replacement and soft tissue repair that enable surgical specialists to improve patients' lives by restoring motion and physical vitality. Market cap at $786.85M, most recent closing price at $19.82. EPS growth next 5 years at 28.33%. Revenue grew by 1.3% during the most recent quarter ($66.01M vs. $65.16M y/y). Inventory grew by -8.13% during the same time period ($79.18M vs. $86.19M y/y). Inventory, as a percentage of current assets, decreased from 40.38% to 38.14% during the most recent quarter (comparing 13 weeks ending 2012-07-01 to 13 weeks ending 2011-07-03).

9. USANA Health Sciences Inc. (NYSE:USNA): Develops, manufactures, distributes, and sells nutritional and personal care products worldwide. Market cap at $664.7M, most recent closing price at $46.0. EPS growth next 5 years at 16%. Revenue grew by 8.04% during the most recent quarter ($160.9M vs. $148.93M y/y). Inventory grew by -4.47% during the same time period ($33.8M vs. $35.38M y/y). Inventory, as a percentage of current assets, decreased from 44.64% to 27.37% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-07-02).

10. Volcano Corporation (NASDAQ:VOLC): Designs, develops, manufactures, and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (FM) products used in the diagnosis and treatment of vascular and structural heart disease. Market cap at $1.47B, most recent closing price at $27.47. EPS growth next 5 years at 26.13%. Revenue grew by 13.48% during the most recent quarter ($95.37M vs. $84.04M y/y). Inventory grew by -6.38% during the same time period ($44.43M vs. $47.46M y/y). Inventory, as a percentage of current assets, decreased from 14.73% to 12.33% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 10 High-Growth Healthcare Stocks With Strong Inventory Trends